Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GHK-Cu Pharmacogenomics & Genetic Variability: How Your Genes Shape Copper Peptide Response

By
Published Updated Last reviewed
13 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Copper-handling genes / ATP7A, ATP7B, SLC31A1 (CTR1) [2][3][4]
  • FDA-approved drug containing GHK-Cu / none known [5]
  • Injectable GHK-Cu / not approved; FDA cites immunogenicity risk [6]
  • Randomized venous-ulcer trial / 86 evaluable patients; 0.4% copper tripeptide cream no better than placebo [7]
  • Normal serum copper on a copper drug label / 80 to 163 mcg/dL [8]

Does genotype change GHK-Cu response?

We found no genotype-stratified GHK-Cu study. The 2026 review screened 1,247 records, kept 64, and found that most human randomized trials are small and use facial cosmetic creams [1]. A 2015 review by the researchers who proposed GHK's mechanisms states that GHK can up- and downregulate at least 4,000 human genes [9]; that describes gene expression in laboratory work, not inherited variation between people.

The copper-handling genes

ATP7A delivers copper to secreted copper enzymes and exports surplus copper from cells; mutations cause Menkes disease, a lethal X-linked disorder of copper metabolism [2]. Copper histidinate (Zycubo) was approved in January 2026 for Menkes disease in children and is a different compound from GHK-Cu [10].

ATP7B mutations cause Wilson disease, with copper accumulating in the liver, brain and other organs; treatment includes chelating agents and zinc salts [3].

SLC31A1 (CTR1) is the high-affinity copper transporter at the cell membrane. In mice, deleting Ctr1 in intestinal cells caused severe defects in copper accumulation in peripheral tissues, identifying Ctr1 as the major factor driving intestinal copper absorption in mammals [4].

Ceruloplasmin carries more than 95% of the copper in plasma, yet a standard review of the protein states it plays no essential role in the transport or metabolism of copper [11].

What a copper drug label says

The FDA label for cupric chloride injection, an intravenous copper supplement for total parenteral nutrition and not a GHK-Cu product, warns that giving copper to patients with Wilson disease may cause increased hepatic copper accumulation and aggravation of the underlying hepatocellular degeneration [8]. It gives normal serum copper as 80 to 163 mcg/dL, mean about 110 mcg/dL, and contraindicates copper in patients with hypersensitivity to copper [8].

What the human trials measured

A randomized trial had 13 patients complete CO2 laser resurfacing of circumoral skin, with or without GHK-Cu skin care afterward. Computer analysis and blinded evaluators found no significant difference in redness resolution, wrinkles or overall skin quality; a patient questionnaire favored GHK-Cu for overall skin quality (P=.04) [12].

In a prospective randomized evaluator-blinded trial, 86 evaluable patients with venous stasis ulcers received a 0.4% tripeptide copper complex cream, an inert vehicle placebo, or silver sulfadiazine 1%. The copper cream was no different from placebo for ulcer size; silver sulfadiazine 1% reduced ulcer size [7].

No FDA-approved drug is known to contain GHK-Cu [5]. Topical copper peptide creams are sold as cosmetics, which do not need FDA approval before sale [13]. Injectable GHK-Cu is not approved, and FDA has stated that compounded injectable drugs containing GHK-Cu may pose an immunogenicity risk from aggregation and peptide-related impurities, with limited human data [6].

Frequently asked questions

Is there a genetic test for copper peptide response?
No. We found no study showing that a genetic test predicts GHK-Cu response, or any GHK-Cu trial that grouped patients by genotype [1]. The clearest gene-copper link with a label warning is Wilson disease (ATP7B): the label of cupric chloride injection, a different product, says copper given to patients with Wilson disease may increase hepatic copper accumulation and aggravate hepatocellular degeneration [3][8].
What did the human GHK-Cu trials show?
The randomized trials found were small. In one, 13 patients had CO2 laser resurfacing and objective measures showed no difference, while a patient questionnaire favored GHK-Cu (P=.04) [12]. In the other, a 0.4% copper tripeptide cream was no better than placebo for venous ulcers in 86 evaluable patients [7].
Is GHK-Cu FDA-approved?
No. No FDA-approved drug is known to contain GHK-Cu. Topical copper peptide creams are sold as cosmetics, which do not need FDA approval before sale, and injectable GHK-Cu is not approved; FDA has cited an immunogenicity risk and limited human data for the injectable route [13][5][6].

References

  1. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
  2. Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. 2010;18(5):511-8. Menkes disease
  3. Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. Wilson disease
  4. Nose Y, Kim BE, Thiele DJ. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. Cell Metab. 2006;4(3):235-44. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function
  5. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  6. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  7. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
  8. U.S. National Library of Medicine, DailyMed. COPPER (cupric chloride) prescribing information. COPPER (cupric chloride) label
  9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
  10. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  11. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr. 2002;22:439-58. Ceruloplasmin metabolism and function
  12. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
  13. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA
Evidence overview for GHK-Cu Pharmacogenomics & Genetic Variability: How Your Genes Shape Copper Peptide Response